Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients - Informazione.it
| ULTI Stock | NOK 1.98 0.05 2.46% |
About 62% of Ultimovacs ASA's investor base is looking to short. The analysis of current outlook of investing in Ultimovacs ASA suggests that many traders are alarmed regarding Ultimovacs ASA's prospects. Ultimovacs ASA's investing sentiment shows overall attitude of investors towards Ultimovacs ASA.
Ultimovacs ASA stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Ultimovacs daily returns and investor perception about the current price of Ultimovacs ASA as well as its diversification or hedging effects on your existing portfolios.
Ultimovacs |
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients Informazione.it
Read at news.google.com
 |
Ultimovacs ASA Fundamental Analysis
We analyze Ultimovacs ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultimovacs ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultimovacs ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Ultimovacs ASA is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Ultimovacs ASA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ultimovacs ASA stock to make a market-neutral strategy. Peer analysis of Ultimovacs ASA could also be used in its relative valuation, which is a method of valuing Ultimovacs ASA by comparing valuation metrics with similar companies.
Peers
Ultimovacs ASA Related Equities
| PCIB | PCI Biotech | 3.45 | ||||
| BGBIO | Bergenbio ASA | 4.23 |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.